| Authors: |
Winkelmayer WC; Section of Nephrology, Baylor College of Medicine, Houston, TX., Arnold S; Excellentis Clinical Trial Consultants, South Africa., Burke SK; Akebia Therapeutics Inc, Cambridge, MA., Chertow GM; Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA., Eckardt KU; Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany., Jardine AG; Department of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK., Lewis EF; Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA., Luo W; Akebia Therapeutics Inc, Cambridge, MA., Matsushita K; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., McCullough PA; Truth for Health Foundation, Tucson, AZ., Minga T; Akebia Therapeutics Inc, Cambridge, MA., Parfrey PS; Division of Nephrology, Memorial University, St John's, Newfoundland, Canada. |
